Aquestive Drops 'Acting In Concert' Disclosure From Its Director-Nomination Bylaw, 8-K Shows

The board rewrote its bylaws on October 15, cutting what a stockholder must say about ties when nominating directors.

Share
Aquestive Drops 'Acting In Concert' Disclosure From Its Director-Nomination Bylaw, 8-K Shows

Aquestive Therapeutics' board adopted amended and restated bylaws on October 15 that remove a disclosure demand on stockholders who nominate directors, according to an 8-K filed Monday. The change deletes the requirement to describe relationships with people "acting in concert with" a nominee.

What the 8-K says

The board approved the new bylaws "in connection with its periodic review of corporate governance matters," and they took effect the same day, October 15, 2026. They replace the prior amended and restated bylaws.

The edit sits in Article I, Section 11, which governs stockholder nominations. Under the old text, a nominating stockholder had to give information about relationships between itself and any "Stockholder Associated Person" on one side, and others "acting in concert with" the nominee, the nominee's immediate family, and the nominee's affiliates and associates on the other. The filing says that requirement was eliminated.

The definition of "Stockholder Associated Person" was also revised. It no longer covers persons "acting in concert with" a nominating stockholder or with the beneficial owners on whose behalf nominations or proposals are brought. The board also made technical, conforming and non-substantive changes.

What stays in place

The bylaw text still requires a nominating stockholder to say whether it intends to solicit holders of at least 67% of the voting power for director nominees other than the company's. Nominees must still complete a questionnaire and a written representation and agreement.

The filing was signed Monday by Chief Financial Officer A. Ernest Toth, Jr. Aquestive shares closed at $3.83 on Monday, up about 1%, before the filing was accepted at 4:04 p.m. ET, so that close is not a reaction to the news.

The full amended bylaws are filed as Exhibit 3.1 to the 8-K, for holders who want the exact wording of Section 11.

Sources

More on Aquestive Therapeutics

All Aquestive Therapeutics (AQST) coverage →